Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13506835 | 0.86 | BCHE (0.33) | BCHEACHENQO2MEN1KMT2A | |
| SCHEMBL13506831 | 0.84 | ALDH1A1 (0.35) | BCHEACHEKDM4EALDH1A1HPGD | |
| SCHEMBL13507568 | 0.79 | BCHE (0.38) | BCHEACHEKDM4EALDH1A1HPGD | |
| SCHEMBL13506824 | 0.75 | NQO2 (0.38) | BCHEACHEKDM4EALDH1A1HPGD | |
| SCHEMBL13507014 | 0.74 | PABPC1 (0.36) | ACHEKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL13070416 | 0.74 | MEN1 (0.34) | ALDH1A1MAPTNPSR1MEN1KMT2A | |
| SCHEMBL13507094 | 0.71 | KIF11 (0.35) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL13506985 | 0.71 | NQO2 (0.35) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL13507157 | 0.71 | IGLV6-57 (0.35) | KDM4EALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL20149501 | 0.71 | ALDH1A1 (0.42) | ACHEKDM4EALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100032658-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100032658-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100032658-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | BCHE 2996/4885ACHE 552/4885KDM4E 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.